Contents
Contents
Compounding ingredient AWP fraud uses inflated average wholesale prices to increase government reimbursement, then sells pharmacies on the profit those prices can produce. The supplier reports the benchmark. The pharmacy buys the ingredient and bills for the compounded prescription. If you work with ingredient invoices, pricing submissions or pharmacy billing, you may see how a low purchase price becomes a much larger claim against a federal health care program.
Average wholesale price is a published benchmark used in reimbursement calculations. Despite its name, it is not a measured average of what pharmacies actually pay. An ingredient supplier can sell a product at one price while reporting another number to the commercial publishers whose pricing data payers use.
A compounding pharmacy combines ingredients to make a medication tailored to a patient. The supplier may sell both the active ingredient and the base, such as a cream or gel, into which it is mixed. In the TRICARE scheme alleged against Professional Compounding Centers of America, each ingredient’s reported AWP helped determine reimbursement for the finished prescription. The complaint describes PCCA’s role from buying and repackaging ingredients to providing formulas and billing support.
The spread is the gap between what the pharmacy pays and what it receives from the payer. A supplier that influences both the selling price and the reimbursement benchmark can make its product attractive by increasing the customer’s potential profit. The sales pitch becomes what the pharmacy can earn from billing for the ingredient.
Actual acquisition cost is what the purchaser pays. We connect the supplier’s sale to the price reported and the payment it generated.
PCCA allegedly inflated ingredient AWPs and used the resulting reimbursement potential to win pharmacy business. The Justice Department joined a case brought by a pharmacist and announced its complaint in November 2021. The pharmacist had worked at and partly owned a compounding pharmacy that bought PCCA’s ingredients and services.
The government’s complaint gives a concrete comparison. In 2014, PCCA allegedly sold fluticasone propionate to certain customers for approximately $135 to $197 per gram while reporting an AWP of about $3,631 per gram. It allegedly sold resveratrol to certain customers for under $2 per gram while reporting an AWP of about $819 per gram.
The complaint alleged that PCCA controlled both numbers. The government’s description of the sales strategy is unusually direct:
PCCA’s scheme was plain and direct: generate mega-spreads to increase pharmacies’ potential profits from using PCCA’s ingredients.
The complaint alleged that PCCA used the inflated benchmarks to charge more than its competitors. When pharmacy customers complained about the higher prices, PCCA emphasized the greater reimbursement potential. The pharmacy could pay more for the ingredient and still expect a larger return from the government.
According to the complaint, senior managers told sales representatives to highlight the spread. PCCA also allegedly rewarded top customers with annual all-inclusive travel packages, advised pharmacies on third-party billing and promoted formulas designed to maximize reimbursement. The alleged mechanism joined the pricing file, the sales conversation and the finished prescription.
The government alleged that PCCA’s customers submitted tens of thousands of compound prescription claims containing its ingredients, and that TRICARE paid hundreds of millions of dollars in excess reimbursement. TRICARE provides healthcare for active-duty military personnel, military retirees and military dependents. The alleged extra profit came out of the program paying for their care.
A supplier can face a False Claims Act case for knowingly causing false claims even when a pharmacy submits them. In the PCCA complaint, the government alleged that the company knew customers would bill TRICARE using its reported AWPs and used the resulting payments to induce ingredient purchases.
The supplier’s own records matter. The pharmacy’s claim shows the bill. Pricing decisions and sales instructions can show how the upstream business helped create it.
The government also alleged that PCCA used inflated spreads as kickbacks to induce ingredient purchases. The alleged reward to the pharmacy came through higher government reimbursement.
Fagron and Medisca agreed to settle allegations of inflated ingredient AWPs long after Medicare Part B moved its ordinary drug payment to average sales price in 2005. Medicaid’s 2016 payment rule also moved toward actual acquisition cost plus a dispensing fee.
Fagron Holding USA agreed to pay $22.05 million in a settlement announced in November 2019. The alleged pricing conduct involved its subsidiary Freedom Pharmaceuticals, which typically sold fluticasone propionate for about $160 per gram while reporting an AWP of $3,500 per gram.
The government alleged that Freedom established inflated ingredient benchmarks and marketed the reimbursement spread to compounding pharmacies. The claims involved TRICARE and the Department of Labor’s workers’ compensation programs.
The settlement resolved allegations in two whistleblower cases. The Justice Department announced a collective whistleblower share of about $3.7 million.
Medisca agreed to pay $21.75 million in a settlement announced in November 2024. The government alleged inflated AWPs for resveratrol and mometasone furoate used in prescriptions billed to TRICARE and federal workers’ compensation.
The alleged resveratrol comparison was stark: Medisca sold the ingredient for under $2 per gram while reporting an AWP of $777 per gram. For mometasone furoate, the government described the chain further upstream. Medisca allegedly acquired it for under $8 per gram, sold it for over $1,000 per gram and reported an AWP of over $7,300 per gram.
Acquisition cost here has two different owners. What Medisca paid to acquire an ingredient and what a pharmacy paid Medisca are separate transactions. The reported benchmark adds another number. Keeping those prices separate shows where the supplier’s margin sits and where the pharmacy’s reimbursement opportunity begins.
A 2010 report by Public Citizen’s Health Research Group found that overcharging government health programs, mainly Medicaid, accounted for the largest number of state pharmaceutical settlements in its study. Its discussion of inflated published prices explains the consequence:
In some cases, state Medicaid programs were paying providers as much as 12 times the actual cost of a drug.
The ingredient cases show the same incentive in another setting: a seller reports a reimbursement benchmark and markets the profit it can create for the buyer.
Invoices, pricing submissions, sales messages and paid claims connect the price difference to the company’s decisions. We compare compounding ingredient AWP versus acquisition price, then follow the evidence through the sales pitch and the reimbursed prescription.
An ingredient invoice shows what the pharmacy paid the supplier. The supplier’s own purchasing records show what it paid further upstream. The reported AWP shows the number made available for reimbursement. Medisca’s alleged pricing chain demonstrates why the purchaser’s identity belongs beside every price.
The formula and billing records connect the ingredient to the prescription. The PCCA complaint describes formulas promoted for reimbursement and advice on submitting claims to third-party payers. Those records can connect a sales promise to what a pharmacy actually billed and what the payer paid.
We also look at who chose the benchmark and how the company sold it. The PCCA allegations put instructions from senior managers beside sales representatives’ pitches. Someone in pricing may know why the AWP changed. Someone in sales may know why a pharmacy accepted a higher ingredient price. Someone in pharmacy billing may see the claim that completed the transaction.
A supplier emphasizing reimbursement profit, promoting formulas for their payment potential or answering price complaints with a larger advertised spread gives a pharmacist a specific reason to look closer. Those are the practices alleged in the PCCA complaint.
The commercial question is what drove the purchase. Was the ingredient being promoted through the amount the pharmacy could bill? We work through that question with the people who saw the pitch, the price and the resulting claims.
Usual-and-customary pricing concerns what a pharmacy charges the general public. Ingredient AWP concerns the benchmark reported for a product.
Kmart’s 2017 settlement concerned allegations that it reported higher usual-and-customary prices instead of the discounted cash prices available through its generic-drug program. Its cash sales and claim forms supplied the comparison, while ingredient AWP cases turn on the supplier’s reported price and sales to pharmacies.
Yes. A pharmacist who owned a compounding pharmacy brought the Medisca case. The Justice Department announced that the whistleblower would receive about $3.4 million from the settlement. The PCCA case also began with a pharmacist at a customer pharmacy.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. A pharmacist’s knowledge of purchases and reimbursement can reach beyond the pharmacy to the supplier that set and promoted the ingredient price.
If you work for an ingredient supplier or compounding pharmacy and know how the benchmark became a sales pitch, speak with our whistleblower experts about the prices and claims you see. We work beside you to build your strongest case from the supplier’s pricing decisions through the pharmacy’s reimbursement. We bring in pharmaceutical fraud whistleblower lawyers who understand ingredient pricing and federal pharmacy claims, and remain your partners throughout the case.